Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Raw Materials (2017 - 2025)

Catheter Precision (VTAK) has disclosed Raw Materials for 9 consecutive years, with $23000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Raw Materials changed N/A to $23000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $23000.0, a N/A change, with the full-year FY2024 number at $18000.0, down 33.33% from a year prior.
  • Raw Materials was $23000.0 for Q3 2025 at Catheter Precision, down from $24000.0 in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $1.9 million in Q2 2021 to a low of $18000.0 in Q4 2024.
  • A 5-year average of $662200.0 and a median of $455500.0 in 2021 define the central range for Raw Materials.
  • Biggest YoY gain for Raw Materials was 66.54% in 2021; the steepest drop was 60.87% in 2021.
  • Catheter Precision's Raw Materials stood at $911000.0 in 2021, then grew by 5.27% to $959000.0 in 2022, then crashed by 97.18% to $27000.0 in 2023, then crashed by 33.33% to $18000.0 in 2024, then increased by 27.78% to $23000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTAK's Raw Materials are $23000.0 (Q3 2025), $24000.0 (Q2 2025), and $24000.0 (Q1 2025).